Akston Biosciences

The Right Shots In The Right Places

Ziad2022-11-25T14:00:30-05:00 Row Covid-19 or Coronavirus vaccine flasks on white background Every safe and effective Covid-19 vaccine is helping to end the global pandemic. But that doesn't mean they're all the same. To succeed globally, though, we can't just focus on what works best on our own shores. A temperature-sensitive vaccine shipped to a facility without freezers will go to waste. Scheduling two doses isn't feasible for every population. In developing countries, these challenges can be acute. More remarkably, Akston Biosciences has begun...

Akston Biosciences and LakePharma Announce Strategic Partnership to Manufacture Second-Generation COVID-19 Vaccine

Ziad2022-11-25T14:02:04-05:00 Akston Biosciences, which develops new classes of biologic therapeutics, and LakePharma, a leading U.S.-based CRDMO serving the biotechnology community, announced today that they have established a strategic partnership. Read more >>

TRACER to support Akston Biosciences’ Phase 1 clinical study of AKS-452, an innovative anti-COVID-19 vaccine

Ziad2022-11-25T14:02:28-05:00 BEVERLY, Mass., USA & GRONINGEN, the Netherlands, Sept. 01, 2020 Today, TRACER Europe B.V., a Clinical Research Organization (CRO) specializing in fast-track solutions for testing innovative biologic medicines, announced that it will support Akston Biosciences Inc., a leader in the development of novel Fc fusion protein therapeutics, in the Phase 1 clinical testing in the Netherlands of Akston’s lead COVID-19 vaccine candidate, AKS-452. Read more >>